Compare TREX & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREX | CPRX |
|---|---|---|
| Founded | 1996 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.4B |
| IPO Year | 1998 | 2006 |
| Metric | TREX | CPRX |
|---|---|---|
| Price | $38.97 | $31.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 1 |
| Target Price | ★ $49.53 | $35.00 |
| AVG Volume (30 Days) | 1.9M | ★ 3.2M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.24 |
| EPS | ★ 0.58 | 0.50 |
| Revenue | ★ $1,174,267,000.00 | $119,072,803.00 |
| Revenue This Year | $5.09 | $9.20 |
| Revenue Next Year | $6.24 | $10.51 |
| P/E Ratio | $66.77 | ★ $62.57 |
| Revenue Growth | 1.98 | ★ 16.39 |
| 52 Week Low | $29.77 | $19.05 |
| 52 Week High | $68.78 | $32.56 |
| Indicator | TREX | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 72.98 |
| Support Level | $35.25 | $22.24 |
| Resistance Level | $44.76 | $31.29 |
| Average True Range (ATR) | 2.00 | 0.31 |
| MACD | -0.06 | -0.13 |
| Stochastic Oscillator | 36.30 | 95.59 |
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.